Diphtheria, Tetanus and Acellular Pertussis

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

CanSino BiologicsChina - Tianjin

3 programs

Diphtheria, Tetanus and Acellular PertussisPhase 31 trial

Adsorbed Acellular PertussisPhase 11 trial

Active Trials

NCT07203755Recruiting260Est. Feb 2029

NCT05951725Active Not Recruiting2,520Est. Apr 2025

NCT06857370Active Not Recruiting780Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2023

2024

2025

2026

2027

2028

2029

CanSino BiologicsDiphtheria, Tetanus and Acellular Pertussis

CanSino BiologicsAdsorbed Acellular Pertussis

Clinical Trials (3)

Total enrollment: 3,560 patients across 3 trials

NCT06857370 CanSino BiologicsDiphtheria, Tetanus and Acellular Pertussis

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine

Start: Mar 2025Est. completion: Jan 2026780 patients

Phase 3Active Not Recruiting

NCT05951725 CanSino BiologicsDiphtheria, Tetanus and Acellular Pertussis

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Start: Aug 2023Est. completion: Apr 20252,520 patients

Phase 3Active Not Recruiting

NCT07203755 CanSino BiologicsAdsorbed Acellular Pertussis

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

Start: Dec 2025Est. completion: Feb 2029260 patients

Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 3,560 patients

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.